Regeneron Pharmaceuticals, Inc. drugs

7 results

  • evkeeza

    (evinacumab)
    Regeneron Pharmaceuticals, Inc.
    EVKEEZA is indicated as an adjunct therapy for adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH). Its safety and effectiveness in other types of hypercholesterolemia, such as heterozygous familial hypercholesterolemia, have not been established.
    Medication Details

  • eylea

    (aflibercept)
    Regeneron Pharmaceuticals, Inc.
    EYLEA is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity.
    Medication Details
    Drug Interactions

  • inmazeb

    (atoltivimab, maftivimab, and odesivimab-ebgn)
    Regeneron Pharmaceuticals, Inc.
    INMAZEB is indicated for treating infections caused by *Orthoebolavirus zairense* in adults and pediatric patients, including neonates born to RT-PCR positive mothers. Its efficacy against other *Orthoebolavirus* species and *Orthomarburgvirus* has not been established. Consider drug susceptibility patterns when using INMAZEB.
    Medication Details
    Drug Interactions

  • libtayo

    (cemiplimab-rwlc)
    Regeneron Pharmaceuticals, Inc.
    LIBTAYO is indicated for treating metastatic or locally advanced cutaneous squamous cell carcinoma in patients unfit for curative surgery/radiation, locally advanced/metastatic basal cell carcinoma following previous hedgehog inhibitor treatment, and for first-line treatment of non-small cell lung cancer in specific adult patients.
    Medication Details
    Drug Interactions

  • praluent

    (alirocumab)
    Regeneron Pharmaceuticals, Inc.
    PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease. It also lowers LDL-C in adults with primary hyperlipidemia or familial hypercholesterolemia and in pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.
    Medication Details
    Drug Interactions

  • veopoz

    (Pozelimab)
    Regeneron Pharmaceuticals, Inc.
    VEOPOZ is indicated for treating adult and pediatric patients aged 1 year and older with CD55-deficient protein-losing enteropathy (PLE), also referred to as CHAPLE disease.
    Medication Details
    Drug Interactions